BioCentury
ARTICLE | Clinical News

AQU-005: Phase I started

August 8, 2016 7:00 AM UTC

NeuroMax began an open-label, Russian Phase I trial to evaluate AQU-005 in 24 healthy volunteers. NeuroMax plans to begin proof-of-concept (POC) trials of the product in patients with neuropathic pain...